Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian H Kushner

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
JCO Precision Oncology|July 12, 2021
Differential Impact of <i>ALK</i> Mutations in NeuroblastomaTara O'Donohue, Nitya Gulati, Audrey Mauguen, et al.
Frontiers in Oncology|January 23, 2023
Skeletal muscle metastases in neuroblastoma share common progenitors with primary tumor and biologically resemble stage MS diseaseChristina Fong, Brian H Kushner, Angela Di Giannatale, et al.
Oncotarget|December 2, 2015
Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoinBrian H Kushner, Irina Ostrovnaya, Irene Y Cheung, et al.
Cold Spring Harbor Molecular Case Studies|June 29, 2017
Germline <i>BRCA2</i> mutations detected in pediatric sequencing studies impact parents' evaluation and careMichael F Walsh, Jennifer Kennedy, Megan Harlan, et al.
Journal of Pediatric Surgery|December 15, 2015
Salvage rates after progression of high-risk neuroblastoma with a soft tissue massJennifer M Murphy, Irene-Isabel P Lim, Benjamin A Farber, et al.
Pediatric Blood & Cancer|February 17, 2005
Long-term complications in survivors of advanced stage neuroblastomaCaroline Laverdière, Nai-Kong V Cheung, Brian H Kushner, et al.
International Journal of Cancer|March 26, 2018
Treatment and outcome of adult-onset neuroblastomaMaya Suzuki, Brian H Kushner, Kim Kramer, et al.
Oncotarget|December 10, 2017
<i>MYCN</i>-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-G<sub>D2</sub> immunotherapyBrian H Kushner, Michael P LaQuaglia, Shakeel Modak, et al.
International Journal of Cancer|August 21, 2023
Stage 4N neuroblastoma before and during the era of anti-G<sub>D2</sub> immunotherapyBrian H Kushner, Michael P LaQuaglia, Fiorella Iglesias Cardenas, et al.
Pediatric Blood & Cancer|November 9, 2022
Clinical outcomes of pediatric patients receiving multimodality treatment of second central nervous system relapse of neuroblastomaKathryn R Tringale, Suzanne L Wolden, Dana L Casey, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
JCO Precision Oncology|July 12, 2021
Differential Impact of <i>ALK</i> Mutations in NeuroblastomaTara O'Donohue, Nitya Gulati, Audrey Mauguen, et al.
Frontiers in Oncology|January 23, 2023
Skeletal muscle metastases in neuroblastoma share common progenitors with primary tumor and biologically resemble stage MS diseaseChristina Fong, Brian H Kushner, Angela Di Giannatale, et al.
Oncotarget|December 2, 2015
Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoinBrian H Kushner, Irina Ostrovnaya, Irene Y Cheung, et al.
Cold Spring Harbor Molecular Case Studies|June 29, 2017
Germline <i>BRCA2</i> mutations detected in pediatric sequencing studies impact parents' evaluation and careMichael F Walsh, Jennifer Kennedy, Megan Harlan, et al.
Journal of Pediatric Surgery|December 15, 2015
Salvage rates after progression of high-risk neuroblastoma with a soft tissue massJennifer M Murphy, Irene-Isabel P Lim, Benjamin A Farber, et al.
Pediatric Blood & Cancer|February 17, 2005
Long-term complications in survivors of advanced stage neuroblastomaCaroline Laverdière, Nai-Kong V Cheung, Brian H Kushner, et al.
International Journal of Cancer|March 26, 2018
Treatment and outcome of adult-onset neuroblastomaMaya Suzuki, Brian H Kushner, Kim Kramer, et al.
Oncotarget|December 10, 2017
<i>MYCN</i>-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-G<sub>D2</sub> immunotherapyBrian H Kushner, Michael P LaQuaglia, Shakeel Modak, et al.
International Journal of Cancer|August 21, 2023
Stage 4N neuroblastoma before and during the era of anti-G<sub>D2</sub> immunotherapyBrian H Kushner, Michael P LaQuaglia, Fiorella Iglesias Cardenas, et al.
Pediatric Blood & Cancer|November 9, 2022
Clinical outcomes of pediatric patients receiving multimodality treatment of second central nervous system relapse of neuroblastomaKathryn R Tringale, Suzanne L Wolden, Dana L Casey, et al.
Pageof 11